Physician profile
Daniel P Krontz
NPI 1326048919
$2,389.00
in general payments reported to CMS, 2019-2025
26 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $296 · 2021: $233 · 2022: $229 · 2023: $415 · 2024: $522 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $420.78 | 2020-2025 | Simbrinza, Clareon, Tryptyr |
| Allergan, INC. | $336.43 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $297.26 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $167.34 | 2020-2023 | |
| Oyster Point Pharma, INC. | $163.72 | 2022-2024 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $133.54 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $107.50 | 2024-2025 | Vevye |
| Abbvie INC. | $106.60 | 2019-2024 | |
| Bausch & Lomb Americas INC. | $105.81 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Dompe US, INC. | $88.49 | 2024-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $80.88 | 2021-2024 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $79.97 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $33.42 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $30.76 | 2019 | |
| Merz Pharmaceuticals, LLC | $26.27 | 2025 | Xeomin |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25.25 | 2024 | Tepezza |
| Thea Pharma INC. | $24.33 | 2023 | |
| Biotissue Holdings INC. | $21.71 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $19.99 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Horizon Therapeutics Plc | $19.06 | 2021 | |
| Maculogix, INC. | $18.31 | 2019 | |
| Shire North American Group INC | $17.58 | 2019 | |
| Lkc Technologies, INC. | $17.34 | 2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $14.70 | 2019 | |
| Omeros Corporation | $12.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Krontz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.